ArticleHeliyon2023
Exploring the biological application of
Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Current challenges and future directions in the green synthesis of nanoparticles using fungi.Bioprocess and biosystems engineering · 2026Article
- Biosynthesis of silver nanoparticles using Musca domestica extract as a novel bioresource for therapeutic evaluation.Discover nano · 2026Article
- Fungal Biofilm: An Overview of the Latest Nano-Strategies.Antibiotics (Basel, Switzerland) · 2025Review
- Mycogenic Silver Nanoparticles: Promising Antimicrobials with Fungistatic Properties.International journal of molecular sciences · 2025Article
- Collagen and chitosan-based biogenic sprayable gel of silver nanoparticle for advanced wound care.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Biosynthesis of Nanoparticles with Green Tea for Inhibition of β-Amyloid Fibrillation Coupled with Ligands Analysis.International journal of nanomedicine · 2024Article
- Bacterial mediated green synthesis of silver nanoparticles and their antibacterial and antifungal activities against drug-resistant pathogens.Royal Society open science · 2023Article
- Biofabrication of Silver Nanoparticles UsingInternational journal of nanomedicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study showed the anti-candida, biofilm inhibitory, antioxidant, anticoagulant, and thrombolytic properties of biogenic silver nanoparticles (AgNPs) fabricated by using the supernatant of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.